O ROURKE & COMPANY Inc Grows Stock Holdings in Pfizer Inc. (NYSE:PFE)

O ROURKE & COMPANY Inc lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 16.8% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 18,790 shares of the biopharmaceutical company’s stock after purchasing an additional 2,709 shares during the quarter. O ROURKE & COMPANY Inc’s holdings in Pfizer were worth $544,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the business. Olistico Wealth LLC acquired a new stake in Pfizer in the 2nd quarter valued at about $25,000. MFA Wealth Advisors LLC acquired a new stake in Pfizer in the second quarter valued at approximately $29,000. Quarry LP purchased a new position in Pfizer in the second quarter worth approximately $31,000. Financial Connections Group Inc. acquired a new position in Pfizer during the 2nd quarter worth approximately $34,000. Finally, ESL Trust Services LLC purchased a new stake in shares of Pfizer in the 1st quarter valued at approximately $37,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

NYSE:PFE traded down $0.07 during trading hours on Thursday, hitting $28.45. The company’s stock had a trading volume of 9,631,561 shares, compared to its average volume of 37,080,367. The company has a market capitalization of $161.22 billion, a PE ratio of 38.38, a PEG ratio of 0.99 and a beta of 0.67. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $31.54. The business’s 50-day moving average is $29.06 and its two-hundred day moving average is $28.56. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same period last year, the firm earned ($0.17) EPS. As a group, research analysts anticipate that Pfizer Inc. will post 2.67 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be issued a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 5.91%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is presently 227.03%.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Wells Fargo & Company boosted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Citigroup began coverage on shares of Pfizer in a research report on Friday, October 25th. They issued a “neutral” rating and a $30.00 target price on the stock. Finally, StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday, October 9th. Eight investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and an average target price of $33.58.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.